CAJ | 학술논문

目的：探讨乳腺癌组织人类表皮生长因子受体2（ Her2）、拓扑异构酶Ⅱ（Topo Ⅱ）表达水平与新辅助化疗近远期疗效的关系。方法：选取96例 TEC 方案新辅助化疗乳腺癌患者，化疗前穿刺活检术与化疗后手术采集病灶组织，采用免疫组化法检测组织Her2、TopoⅡ表达水平。结果：新辅助化疗后，Her2、TopoⅡ阳性表达率（60．42％、80．21％）较化疗前（88．54％、92．71％）显著降低（P＜0．05）；且有效组的Her 2、TopoⅡ阳性表达率显著低于无效组，阴性表达率显著高于无效组，两组比较差异具有统计学意义（P＜0．05），Her2、TopoⅡ阴性组的化疗有效率与1、3、5年生存率均显著高于阳性组，两组比较差异性显著（ P＜0．05）。结论：新辅助化疗通过降低乳腺癌组织Her2、TopoⅡ阳性表达以增强患者的化疗效果，且Her2、TopoⅡ表达水平在近远期疗效的预测中具有重要的临床价值。
목적：탐토유선암조직인류표피생장인자수체2（ Her2）、탁복이구매Ⅱ（Topo Ⅱ）표체수평여신보조화료근원기료효적관계。방법：선취96례 TEC 방안신보조화료유선암환자，화료전천자활검술여화료후수술채집병조조직，채용면역조화법검측조직Her2、TopoⅡ표체수평。결과：신보조화료후，Her2、TopoⅡ양성표체솔（60．42％、80．21％）교화료전（88．54％、92．71％）현저강저（P＜0．05）；차유효조적Her 2、TopoⅡ양성표체솔현저저우무효조，음성표체솔현저고우무효조，량조비교차이구유통계학의의（P＜0．05），Her2、TopoⅡ음성조적화료유효솔여1、3、5년생존솔균현저고우양성조，량조비교차이성현저（ P＜0．05）。결론：신보조화료통과강저유선암조직Her2、TopoⅡ양성표체이증강환자적화료효과，차Her2、TopoⅡ표체수평재근원기료효적예측중구유중요적림상개치。
Objective:To study relativity between human epidermal growth factor receptor 2 ( Her2 ) , topoisomerase II(Topo II)expression level in breast cancer tissue and short /long-term effect of neoadjuvant chemotherapy .Method:96 cases TEC neoadjuvant chemotherapy breast cancer patients were selected , using biopsy before chemotherapy and surgery after chemotherapy to collect lesions and immunohistochemical meth -od to detect level of tissue Her 2, Topo II expression .Result:After neoadjuvant chemotherapy , Her2, Topo II positive expression rate (60.42%, 80.21%) significantly decreased than before (88.54%, 88.54%) (P <0.05); And Her2, Topo II positive expression rate of effective group were significantly lower than ineffective group, Her2, Topo II negative expression rate were also significantly higher than ineffective group ( P <0. 05), and effective rate and 1, 3, 5 year survival rates in Her2, Topo II negative groups were significantly higher than those in positive group (P <0.05).Conclusion:Neoadjuvant chemotherapy can reduce breast tissue Her2, Topo II positive expression to enhance chemotherapy effect , and Her2, Topo II expression level has important clinical value in predicting of short/long-term effect.